Table of Contents Author Guidelines Submit a Manuscript
Volume 18 (2004), Issue 4, Pages 597-603

Biodistribution and biocompatibility investigation in magnetoliposome treated mice

Z. G. M. Lacava,1,5 V. A. P. Garcia,1 L. M. Lacava,1 R. B. Azevedo,1 O. Silva,2 F. Pelegrini,2 M. De Cuyper,3 and P. C. Morais4

1Universidade de Brasília, Instituto de Ciências Biológicas, 70910‒900, Brasília-DF, Brazil
2Universidade Federal de Goiás, Instituto de Física, 74001-970, Goiânia-GO, Brazil
3K.U. Leuven Campus Kortrijk, Interdisciplinary Research Center, E. Sabbelaan 53, B‒8500 Kortrijk, Belgium
4Universidade de Brasília, Instituto de Física, Núcleo de Física Aplicada, 70919-970, Brasília-DF, Brazil
5Universidade de Brasília, Instituto de Ciências Biológicas, Depto de Genética e Morfologia, 70910-900, Brasília-DF, Brazil

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Magnetoliposomes (ML's) may be successfully applied for several purposes. A dimyristoylphosphatidyl‒choline‒based ML (ML‒2) sample was developed as a precursor of more complex thermal cancer therapy systems. The present study reports on morphology and magnetic resonance (MR) investigations carried out with the magnetite‒based ML‒2 sample. For the experiments, adult female Swiss mice were endovenously treated with a bolus dose of 100 µl of ML‒2. Morphology and room‒temperature MR studies (X‒band experiments) were performed in several organs collected from 1 hour to 28 days after ML administration. Histological data showed magnetic nanoparticle (MNP) clusters up to the 28th day in the liver and spleen tissues. In spite of the presence of MNP clusters, no morphological alterations were observed, supporting the biocompatibility of the ML‒2. MR signal was detected only in the liver and spleen tissues and showed that the MNP's concentration was not altered from 48 hours to 28 days after ML injection. Using MR data, important pharmacokinetic parameters, such as the effective clearance (half‒life) and peak concentration, were obtained for the liver and spleen.